                               SEQUENCE LISTING

<110> THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE 
      SECRETARY OF THE ARMY, ON BEHALF OF THE UNITED STATES ARMY 
      MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES
 
<120> ANTIVIRAL RIFT VALLEY FEVER VIRUS PEPTIDES AND METHODS OF USE

<130> ARMY203PCT

<140>
<141>

<150> 61/733,966
<151> 2012-12-06

<160> 12    

<170> PatentIn version 3.5

<210> 1
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 1
Tyr Trp Thr Gly Ser Ile Ser Pro Lys Cys Leu Ser Ser Arg Arg Cys 
1               5                   10                  15      


His Leu Val 
            


<210> 2
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 2
Trp Gly Cys Gly Cys Phe Asn Val Asn Pro Ser Cys Leu Phe Val His 
1               5                   10                  15      


Thr Tyr Leu 
            


<210> 3
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 3
Leu Gly Ala Ser Ser Ser Arg Phe Thr Asn Trp Gly Ser Val Ser Leu 
1               5                   10                  15      


Ser Leu Asp 
            


<210> 4
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 4
Phe Val Gly Ala Ala Val Ser Cys Asp Ala Ala Phe Leu Asn Leu Thr 
1               5                   10                  15      


Gly Cys Tyr 
            


<210> 5
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 5
Trp Asn Phe Phe Asp Trp Phe Ser Gly Leu Met Ser Trp Phe Gly Gly 
1               5                   10                  15      


Pro Leu Lys Leu Tyr 
            20      


<210> 6
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 6
Trp Asn Phe Phe Asp Trp Phe Ser Gly Leu Met Ser Trp Phe Gly Gly 
1               5                   10                  15      


Pro Leu Lys 
            


<210> 7
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 7
Trp Asn Phe Phe Asp Trp Phe Ser Gly Leu Met Ser Trp Phe Gly Gly 
1               5                   10                  15      


Pro Leu Lys Thr Ile 
            20      


<210> 8
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 8
Ser Trp Asn Phe Phe Asp Trp Phe Ser Gly Leu Met Ser Trp Phe Gly 
1               5                   10                  15      


Gly Pro Leu Lys 
            20  


<210> 9
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 9
Ser Gly Ser Trp Asn Phe Phe Asp Trp Phe Ser Gly Leu Met Ser Trp 
1               5                   10                  15      


Phe Gly Gly 
            


<210> 10
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 10
Ser Gly Ser Trp Asn Phe Phe Asp Trp Phe Ser Gly Leu Met Ser Trp 
1               5                   10                  15      


Phe Gly Gly Pro Leu 
            20      


<210> 11
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 11
Met Phe Leu Gly Trp Ser Phe Asp Phe Gly Ser Leu Trp Gly Asn Lys 
1               5                   10                  15      


Pro Trp Phe 
            


<210> 12
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 12
Trp Ser Ser Gly Leu Pro Phe Gly Asn Phe Gly Leu Ser Trp Phe Asp 
1               5                   10                  15      


Met Gly Phe Trp Ser 
            20      


